Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Ann Palliat Med. 2021 Jun;10(6):6198-6207. doi: 10.21037/apm-20-2170. Epub 2021 May 17.
Research has shown that acute kidney injury (AKI) has a noticeable incidence in critically ill patients with coronavirus disease 2019 (COVID-19). Patients with prior renal insufficiency are particularly susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), due to their immune dysfunction. However, most patients with COVID-19 do not have a history of kidney dysfunction, and few studies have focused on the incidence of AKI among COVID-19 patients without chronic kidney disease (CKD). In this study, we aimed to investigate the occurrence of AKI in severely and critically ill COVID-19 patients, with a particular focus on those without a CKD history.
A single-center retrospective study of 96 patients with COVID-19 in China between February 7 and March 3, 2020 was conducted. All patients were diagnosed by nucleic acid test (NAT) for SARS-CoV-2. Enrolled patients were divided into the severely or critically ill group according to the defined criteria. Patients' epidemiological, clinical, and laboratory characteristics, along with their treatment information, were collected from the medical history system. The occurrence of AKI was compared between the severe and critical patients, and between patients with or without a history of CKD. The diagnostic criteria for AKI included an increase in the serum creatinine level to ≥1.5-fold the level at baseline within 7 days according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Renal outcomes were defined as AKI or non-AKI.
Four patients (4.2%) developed AKI, all of whom were in the critically ill group, and 3 (75%) of whom died. Out of the 90 severely and critically ill COVID-19 patients without CKD, 3 (3.3%) patients developed AKI; out of the 6 patients with CKD, 1 (16.7%) patient developed AKI. Age, disease severity, procalcitonin, C-reactive protein, and interleukin-6 were correlated with AKI onset in severely and critically ill COVID-19 patients, while lymphocyte count and estimated glomerular filtration rate at admission were inversely related to the development of AKI.
Only 3.3% of severely and critically ill COVID-19 patients without CKD in our research cohort developed AKI. Critically ill patients may be more susceptible to AKI than severely ill patients.
研究表明,急性肾损伤(AKI)在患有 2019 年冠状病毒病(COVID-19)的危重症患者中发生率较高。由于免疫功能障碍,既往肾功能不全的患者特别容易受到严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)的影响。然而,大多数 COVID-19 患者没有肾功能障碍的病史,很少有研究关注没有慢性肾脏病(CKD)的 COVID-19 患者的 AKI 发生率。在这项研究中,我们旨在调查严重和危重症 COVID-19 患者中 AKI 的发生情况,特别关注那些没有 CKD 病史的患者。
对 2020 年 2 月 7 日至 3 月 3 日期间在中国进行的 96 例 COVID-19 患者进行了单中心回顾性研究。所有患者均通过核酸检测(NAT)对 SARS-CoV-2 进行诊断。根据既定标准,将纳入患者分为严重或危重症组。从病历系统中收集患者的流行病学、临床和实验室特征以及治疗信息。比较严重和危重症患者之间以及有或没有 CKD 病史的患者之间 AKI 的发生情况。AKI 的诊断标准包括根据肾脏疾病:改善全球结局(KDIGO)指南,血清肌酐水平在 7 天内升高至基线水平的 1.5 倍以上。肾脏结局定义为 AKI 或非 AKI。
有 4 名(4.2%)患者发生 AKI,均在危重症组,其中 3 名(75%)死亡。在 90 名没有 CKD 的严重和危重症 COVID-19 患者中,有 3 名(3.3%)患者发生 AKI;在 6 名 CKD 患者中,有 1 名(16.7%)患者发生 AKI。年龄、疾病严重程度、降钙素原、C 反应蛋白和白细胞介素-6 与严重和危重症 COVID-19 患者 AKI 的发生相关,而入院时的淋巴细胞计数和估计肾小球滤过率与 AKI 的发生呈负相关。
在我们的研究队列中,只有 3.3% 的没有 CKD 的严重和危重症 COVID-19 患者发生 AKI。危重症患者可能比重症患者更容易发生 AKI。